Projects
Development of small-molecule inhibitors of nonmuscle myosin II as chemical tools and antimetastatic therapeutics (CONFIDENTIAL) Ghent University
The present proposal envisages the development of potent, isoform-selective small-molecule nonmuscle myosin II-inhibitors, based on the ‘confirmed hit’ blebbistatin. Such molecules have the potential to become highly valuable tools in the study of cell motility and malignant disease, and serve as leads for targeted anti-invasive pharmacotherapeutics with lowered resistance susceptibility.
Development of small-molecule inhibitors targeting pro-inflammatory and pruritogenic IL-31 Ghent University
The cytokine IL-31 and its cognate receptors (IL31R and OSMR) are validated molecular targets for the treatment of atopic dermatitis and associated chronic itch. The prevalence of such a disease combination is considerably high worldwide and keeps rising. To respond to such a large scale growing medical need, the drug market against atopic dermatitis keeps growing and is repositioning itself towards more effective and affordable ...
EVZYM: A new source of native human targets in high throughput screening (HTS) of enzyme inhibitors – TMPRSS2 as an example. University of Antwerp
A novel class of reversible Exportin-1 inhibitors for cancer therapy KU Leuven
Cellular CD4 receptor inhibitors as a novel anti-HIV therapy. KU Leuven
Novel HIV inhibitors targeting the interaction between integrase and LEDGF/p75 KU Leuven
</>
There is a ...
Exploiting structural insights in IP3 receptor function to develop novel, allosteric inhibitors of IP3 receptor channels (SINFONIC) KU Leuven
Validation of small molecule inhibitors of MALT1 protease for the treatment of auto-immune disorders and NF-κB-addicted lymphomas. KU Leuven
Current scientific literature highlights MALT1 protease activity as an important therapeutic target for treating NF-κB-mediated diseases such as autoimmune disorders and lymphoma. In collaboration with CD3 we have developed and patented three classes of MALT1 small molecule inhibitors that affect MALT1 substrate cleavage in cells and that reduce processes regulated by MALT1 protease activity such as IL2 production by and proliferation of ...